Unity Biotechnology Shuts Down Staff, Including CEO, as Future Remains Uncertain
South San Francisco-based biotech firm Unity Biotechnology, once valued at $700 million, has laid off its entire workforce — including CEO Anirvan Ghosh — as it struggles to stay afloat.
In a press release and SEC filing issued Monday, the company confirmed it will let go of all remaining employees by May 15, turning instead to part-time consultants to tie up loose ends and assist in exploring “strategic alternatives.” These include selling off assets, merging with another company, or potentially shutting down completely.
Unity’s dramatic step comes amid years of downsizing and financial losses. The firm — known for its once-promising research into aging and age-related diseases — peaked with 65 employees in 2021 but had just 16 remaining by the end of 2024. As of March, Unity reported $16.9 million in cash reserves. Severance packages and related costs from this latest move are expected to cost around $3.7 million.
CEO to Stay On — Part-Time
CEO Anirvan Ghosh, along with the company’s CFO and chief legal officer, will transition into consulting roles and receive severance payments ranging from nine to 12 months of their salaries. Ghosh will remain on to help finalize data from Unity’s lead drug candidate — a treatment for diabetic macular edema — and assist with any upcoming partnerships. Full trial results are expected to be presented Wednesday.
Despite the layoff announcement, Ghosh used Monday’s statement to promote the company’s drug development prospects, suggesting that the eye disease program could still attract interest from companies with existing infrastructure in ophthalmology.
Trump Meets Canada New Prime Minister After Controversial ‘51st State’ Comments
From Anti-Aging Hype to Collapse
Unity was founded with bold ambitions: to develop therapies targeting senescent cells — cells that stop dividing but don’t die, contributing to tissue degradation and aging-related diseases. The idea drew early attention from high-profile investors like Jeff Bezos and Peter Thiel and media coverage from outlets such as Forbes and CNBC.
Back in 2018, co-founder Nathaniel David told CNBC: “The time has finally arrived that our knowledge of biology and our sophistication level is sufficient that we can attack some of these fundamental, underlying causes of aging.”
That vision never materialized. A major osteoarthritis trial failed in 2020, followed by disappointing results from an eye disease study in 2023. Despite the optimism, Unity has burned through more than $510 million in investor funds without bringing a single drug to market — a risk not uncommon in the biotech world, but a devastating blow nonetheless.
Market Cap Plunges
As of Monday, Unity’s market valuation stood at just $19 million — a far cry from its IPO valuation of $700 million in 2018. The company has not responded to media inquiries regarding its current status or future plans.
What began as a promising biotech startup aiming to redefine aging may now be nearing its final chapter. Unless Unity can strike a deal or offload its remaining assets, the once-celebrated firm may soon disappear altogether from the life sciences landscape.
Thanks for visiting Best Breaking News
